Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FANCOLEN-1: Gene therapy for Fanconi Anemia Subtype A
NCT03157804Phase 2Completed
- Sponsor
- Hospital Universitario Niño Jesús
- Start
- Jan 2016
- Primary completion
- Apr 2019
- Modality
- Gene Editing, Gene Silencing, Stem Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of PGK-FANCA-Wpre* transduced CD34+ cells in Fanconi anemia complementation group A (FA-A), sponsored by Hospital Universitario Niño Jesús. Started Jan 2016; status: completed.
02
Drugs
PGK-FANCA-Wpre* transduced CD34+ cells
03
Conditions
Fanconi anemia complementation group A (FA-A)
Beyond the preview
Go deeper on NCT03157804.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03157804.